In a phase 3 clinical trial, tirzepatide, a dual GIPR/GLP1R agonist, was shown to confer superior HbA1c control as compared to GLP1R agonism alone and has recently been approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes treatment.12 Here, GLP1R is linked to type 2 diabetes mellitus.